Related Experiment Video

Updated: Apr 11, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K

Expanding the Reach of Anti-PD-1 Therapy

    Cancer Discovery
    |June 3, 2015
    PubMed

    Insights

    Anti-PD-1 drugs show promise beyond melanoma. Pembrolizumab and nivolumab demonstrated significant efficacy in head and neck, liver, and non-small cell lung cancers.

    Area of Science:

    • Oncology
    • Immunotherapy
    • Cancer Research

    Background:

    • Melanoma treatment has seen advances with anti-PD-1 therapies.
    • Further investigation is needed to explore the efficacy of these agents in other cancer types.

    Purpose of the Study:

    • To evaluate the effectiveness of anti-PD-1 drugs in various advanced cancers.
    • To compare pembrolizumab with cetuximab in head and neck squamous cell carcinoma.
    • To assess nivolumab's activity in liver cancer and non-small cell lung cancer.

    Main Methods:

    • Analysis of results from three clinical studies, including KEYNOTE-012 and CheckMate 057.
    • Comparative effectiveness of pembrolizumab versus cetuximab.
    • Assessment of nivolumab for durable antitumor activity and overall survival.

    Main Results:

    • Pembrolizumab demonstrated twice the efficacy of cetuximab in advanced head and neck squamous cell carcinoma.
    • Nivolumab showed durable antitumor activity in patients with advanced liver cancer.
    • Nivolumab treatment led to extended median overall survival in advanced non-squamous non-small cell lung cancer.

    Conclusions:

    • Anti-PD-1 therapies, including pembrolizumab and nivolumab, represent a promising treatment avenue for cancers beyond melanoma.
    • These findings support the broader application of immune checkpoint inhibitors in diverse oncological settings.

    More Related Videos

    Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

    Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

    Published on: February 5, 2020

    6.3K
    Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction10:18

    Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

    Published on: July 7, 2023

    1.8K

    Related Concept Videos

    Tumor Immunotherapy01:27

    Tumor Immunotherapy

    Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
    2.5K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    9.2K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    1.8K
    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    1.5K
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.9K